These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 28074293)

  • 61. Practical recommendations on incorporating new oral anticoagulants into routine practice.
    Randhawa J; Thiruchelvam N; Ghobrial M; Spiro T; Clark B; Haddad A; Daw H
    Clin Adv Hematol Oncol; 2014 Oct; 12(10):675-83. PubMed ID: 25658892
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Drug Treatment of Venous Thromboembolism in the Elderly.
    Boey JP; Gallus A
    Drugs Aging; 2016 Jul; 33(7):475-90. PubMed ID: 27255713
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease.
    De Caterina R; Husted S; Wallentin L; Andreotti F; Arnesen H; Bachmann F; Baigent C; Collet JP; Halvorsen S; Huber K; Jespersen J; Kristensen SD; Lip GY; Morais J; Rasmussen LH; Ricci F; Sibbing D; Siegbahn A; Storey RF; Ten Berg J; Verheugt FW; Weitz JI
    Thromb Haemost; 2016 Apr; 115(4):685-711. PubMed ID: 26952877
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Overview of the new oral anticoagulants: opportunities and challenges.
    Yeh CH; Hogg K; Weitz JI
    Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1056-65. PubMed ID: 25792448
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study.
    Staerk L; Gerds TA; Lip GYH; Ozenne B; Bonde AN; Lamberts M; Fosbøl EL; Torp-Pedersen C; Gislason GH; Olesen JB
    J Intern Med; 2018 Jan; 283(1):45-55. PubMed ID: 28861925
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Anticoagulation and Renal Insufficiency.
    Koulouri A; Calanca L; Mazzolai L
    Ther Umsch; 2016; 73(10):567-572. PubMed ID: 28045357
    [No Abstract]   [Full Text] [Related]  

  • 68. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
    Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
    Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Perioperative management of patients on NOACs].
    Kelm C; Engels K
    Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):125-128. PubMed ID: 28083624
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Direct oral anticoagulants: An update.
    Franco Moreno AI; Martín Díaz RM; García Navarro MJ
    Med Clin (Barc); 2018 Sep; 151(5):198-206. PubMed ID: 29295790
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Safety of cataract surgery in patients treated with the new oral anticoagulants (NOACs).
    Barequet IS; Zehavi-Dorin T; Bourla N; Tamarin I; Moisseiev J; Salomon O
    Graefes Arch Clin Exp Ophthalmol; 2019 Dec; 257(12):2671-2676. PubMed ID: 31641883
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation.
    Esteve-Pastor MA; Rivera-Caravaca JM; Roldán V; Orenes-Piñero E; Romiti GF; Romanazzi I; Bai Y; Carmo J; Proietti M; Marín F; Lip GYH
    Am J Cardiol; 2018 Sep; 122(5):785-792. PubMed ID: 30049460
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET.
    Grandone E; Aucella F; Barcellona D; Brunori G; Forneris G; Gresele P; Marietta M; Poli D; Testa S; Tripodi A; Genovesi SC
    Blood Transfus; 2020 Nov; 18(6):478-485. PubMed ID: 33000751
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
    Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
    Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
    Plitt A; Ruff CT; Giugliano RP
    Hematol Oncol Clin North Am; 2016 Oct; 30(5):1019-34. PubMed ID: 27637305
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Ninety-day prognosis of patients receiving direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: The real life evidence.
    Masotti L; Grifoni E; Dei A; Vannucchi V; Moroni F; Spolveri S; Panigada G; Landini G
    Thromb Res; 2018 Dec; 172():165-168. PubMed ID: 30419471
    [No Abstract]   [Full Text] [Related]  

  • 78. Trends in the prescription of novel oral anticoagulants in UK primary care.
    Loo SY; Dell'Aniello S; Huiart L; Renoux C
    Br J Clin Pharmacol; 2017 Sep; 83(9):2096-2106. PubMed ID: 28390065
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: who, where and for how long?
    Howard LS
    Expert Rev Respir Med; 2018 May; 12(5):387-402. PubMed ID: 29542359
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Why switch from warfarin to NOACs?
    Verdecchia P; Angeli F; Aita A; Bartolini C; Reboldi G
    Intern Emerg Med; 2016 Apr; 11(3):289-93. PubMed ID: 26972708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.